[{"orgOrder":0,"company":"CNBX Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidivarin","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CNBX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CNBX Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"CNBX Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Cannabidivarin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : The company plans to examine the clinical safety and efficacy of the novel formulation which contains high concentrations of the cannabinoids CBDV and CBGA in a proprietary formulation.

Brand Name : Undisclosed

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 13, 2020

Lead Product(s) : Cannabidivarin

Therapeutic Area : Oncology

Highest Development Status : Preclinical

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank